Literature DB >> 1448423

Acyclovir permeation enhancement across intestinal and nasal mucosae by bile salt-acylcarnitine mixed micelles.

G B Park1, Z Shao, A K Mitra.   

Abstract

The purpose of this study was to investigate the absorption enhancement of acyclovir, an antiviral agent, by means of bile salt-acylcarnitine mixed micelles. The specificity, site dependence, palmitoyl-DL-carnitine chloride (PCC) concentration dependence, and effects of absorption promoters on acyclovir absorption via the nasal cavity (N) and four different intestinal segments of the rat, i.e., duodenum (D), upper jejunum (UJ), combined lower jejunum and ileum (LJ), and colon (C) were evaluated. The present study employed the rat in situ nasal and intestinal perfusion techniques and utilized sodium glycocholate (NaGC), three acylcarnitines, and their mixed micelles as potential nasal and intestinal absorption promoters. Acylcarnitines used were DL-octanoylcarnitine chloride (OCC), palmitoyl-DL-carnitine chloride (PCC), and DL-stearoylcarnitine chloride (SCC). All acylcarnitines and NaGC by themselves produced negligible enhancement of acyclovir absorption in the rat intestine, while OCC and SCC were totally ineffective in the nasal cavity. However, the mixed micellar solutions of NaGC with PCC or SCC could significantly increase the mucosal membrane permeability of acyclovir in the colon and nasal cavity. On the other hand, NaGC-OCC mixed micelles slightly increased the absorption of acyclovir by both routes. When a mixed micellar solution of NaGC with PCC was used, the rank order of apparent acyclovir permeability (Papp; cm/sec), corrected for surface area of absorption, was N (10.54 +/- 0.62 x 10(-5)) > D (6.82 +/- 0.30 x 10(-5)) > LJ (2.90 +/- 0.08 x 10(-5)) > C (2.54 +/- 0.14 x 10(-5)) > UJ (2.30 +/- 0.22 x 10(-5)).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448423     DOI: 10.1023/a:1015845031488

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

Review 1.  Alternative delivery systems for peptides and proteins as drugs.

Authors:  D A Eppstein; J P Longenecker
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1988       Impact factor: 4.889

Review 2.  Intestinal drug absorption enhancement: an overview.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

Review 3.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

4.  Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats.

Authors:  M Mishima; Y Wakita; M Nakano
Journal:  J Pharmacobiodyn       Date:  1987-11

5.  Mechanism and site dependency of intestinal mucosal transport and metabolism of thymidine analogues.

Authors:  G B Park; A K Mitra
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

Review 6.  Carnitine--metabolism and functions.

Authors:  J Bremer
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

7.  The disposition of acyclovir in different species.

Authors:  P de Miranda; H C Krasny; D A Page; G B Elion
Journal:  J Pharmacol Exp Ther       Date:  1981-11       Impact factor: 4.030

8.  Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats.

Authors:  C H Huang; R Kimura; R B Nassar; A Hussain
Journal:  J Pharm Sci       Date:  1985-06       Impact factor: 3.534

Review 9.  Pharmacokinetics of acyclovir after intravenous and oral administration.

Authors:  P de Miranda; M R Blum
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

10.  Carnitine and carnitine esters in rat bile and human duodenal fluid.

Authors:  J J Hamilton; P Hahn
Journal:  Can J Physiol Pharmacol       Date:  1987-09       Impact factor: 2.273

View more
  7 in total

1.  Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.

Authors:  Sumeet Dhaliwal; Subheet Jain; Hardevinder P Singh; A K Tiwary
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

2.  Piperine containing floating microspheres: an approach for drug targeting to the upper gastrointestinal tract.

Authors:  Smriti Khatri; Rajendra Awasthi
Journal:  Drug Deliv Transl Res       Date:  2016-06       Impact factor: 4.617

3.  The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs.

Authors:  Z Shao; G B Park; R Krishnamoorthy; A K Mitra
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

4.  Nasal absorption in the rat. III. Effect of lysophospholipids on insulin absorption and nasal histology.

Authors:  S G Chandler; N W Thomas; L Illum
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 5.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

6.  Formulation and optimization of mucoadhesive nanodrug delivery system of acyclovir.

Authors:  Uv Bhosale; Devi V Kusum; N Jain
Journal:  J Young Pharm       Date:  2011-10

7.  The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans.

Authors:  Marlies Kubbinga; Mai Anh Nguyen; Petra Staubach; Steven Teerenstra; Peter Langguth
Journal:  Pharm Res       Date:  2015-01-22       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.